Tirzepatide is a dual agonist that simultaneously targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. It is primarily indicated for the treatment of type 2 diabetes in adults, aiding patients in managing their condition by improving glycaemic control. Furthermore, tirzepatide is being investigated for its potential benefits in weight management, demonstrating significant weight loss effects.
Retatrutide is a triple agonist targeting GLP-1, GIP, and GCGR (glucagon receptor) simultaneously. It is primarily under investigation for the treatment of obesity and non-alcoholic fatty liver disease (NAFLD), and holds promise as a research direction for a new generation of weight-loss medications.
Lemon Bottle fat-dissolving injections are primarily employed for localised weight reduction, such as diminishing fat deposits in specific facial and bodily areas. They can assist in refining facial contours, reducing double chins, and enhancing skin elasticity.
Business Process
|
|
|
|
|
|
|
|
The difference
♦ Tirzepatide
1) Clinical efficacy: Tirzepatide has been approved for the treatment of type 2 diabetes and is currently being investigated for weight management. In clinical trials, it has demonstrated significant weight reduction effects, with average weight loss reaching 20% to 22%, making it one of the most effective weight management medications currently available.
2) Safety: The safety profile of tirzepatide is comparable to other GLP-1 receptor agonists. Common adverse events include gastrointestinal reactions (such as nausea, diarrhoea, constipation), though these are predominantly mild to moderate in severity and most frequently observed during dose escalation phases.
♦ Retatrutide
1) Clinical efficacy: Retatrutide remains in the clinical trial phase, though preliminary research indicates significant weight reduction effects. For instance, a Phase II weight loss study demonstrated that subjects in the 12mg Retatrutide group achieved a 17.5% reduction in body weight after 24 weeks of treatment, with the weight loss reaching 24.2% when extended to 48 weeks.
2) Safety: As Retatrutide remains in clinical trials, long-term safety data are currently insufficient. However, existing data suggest its safety profile appears comparable to other GLP-1 receptor agonists, with common adverse events including gastrointestinal reactions such as nausea, vomiting, and diarrhoea.
♦ Lemon bottle
1) Clinical efficacy: Lemon Bottle fat-dissolving injections are primarily used for localised weight reduction, such as diminishing fat deposits in specific facial and bodily areas. They may assist in refining facial contours, reducing double chins, and enhancing skin elasticity. However, results vary between individuals and multiple sessions are typically required to achieve desired outcomes.
2) Safety: The safety of Lemon Bottle fat-dissolving injections depends on both the formulation and injection technique. Generally, if the product ingredients are safe and the injection is administered correctly, the risks are relatively low. Nevertheless, all injection treatments carry inherent risks, including infection and allergic reactions.
Application
Treatment of type 2 diabetes in adults
Significant reduction in blood glucose: Tirzepatide demonstrates excellent efficacy in glycaemic control, significantly lowering haemoglobin A1c (HbA1c) levels. For instance, in the SURPASS-5 clinical trial, the 5 mg dose group achieved a 2.11% reduction in HbA1c over 40 weeks, while the 15 mg dose group achieved a 2.34% reduction.
Improved metabolic status: Tirzepatide also enhances patients' metabolic status, including lowering blood lipid levels and improving insulin sensitivity.
Obesity Treatment
Mechanism of Action: Retatrutide reduces energy intake and increases expenditure through dual mechanisms of central appetite suppression (via GLP-1R/GIPR) and peripheral lipolysis (via GCGR). Specifically, activation of GLP-1R delays gastric emptying and diminishes appetite; activation of GIPR directly influences the brain's satiety centres to reduce hunger sensations. while GCGR activation increases energy expenditure and promotes fat oxidation.
Clinical Efficacy: In Phase 2 clinical trials involving obese patients, Retatrutide demonstrated significant weight loss effects. For instance, the 12mg dose group achieved an average weight reduction of 24.2% after 48 weeks of treatment, with the highest dose group approaching 30%. Furthermore, the drug achieved 100% success in achieving 5% weight loss (a clinically beneficial weight reduction).
Fat-dissolving
Breakdown of fat cells: Bromelain breaks down fat cell membranes, converting fat into fatty acids.
Promotes metabolic elimination: Lecithin and riboflavin assist in expelling fatty acids through the lymphatic system and urinary tract.
Improves skin condition: Ingredients such as Centella asiatica extract and chamomile extract stimulate collagen production, enhancing skin elasticity.
Common features
► Target Mechanism
Tirzepatide: As a dual receptor agonist, it simultaneously activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, primarily acting upon the hormonal systems regulating blood glucose and body weight.
Retatrutide: As a triple receptor agonist, it simultaneously activates GLP-1, GIP, and GCGR (glucagon receptor) receptors, offering broader action across multiple metabolism-related hormonal systems.
Lemon bottle peptide (if its core component is a lipolytic peptide): Should its core component include peptides such as bromelain, it primarily targets adipocytes, reducing fat accumulation by degrading adipocyte membranes or promoting fat metabolism.
Commonality: All three act on specific physiological systems or cell types, aiming to improve metabolic health or body composition.
► Mechanism of Action
Tirzepatide: Significantly improves glycaemic control by promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying. It also reduces energy intake to achieve weight loss.
Retatrutide: Exerts dual effects through central appetite suppression and peripheral lipolysis, thereby reducing hunger, increasing energy expenditure, and promoting fat oxidation to deliver enhanced weight loss outcomes.
Lemon bottle peptide (if its core component is a lipolytic peptide): Directly reduces fat accumulation by breaking down adipocyte membranes or promoting fat metabolism, potentially accompanied by anti-inflammatory and skin-firming effects.
Common Features: All three function by regulating physiological processes or cellular metabolism to improve metabolic health or body composition. Though their specific mechanisms differ, they all involve modulating hormones, enzymes, or cellular activity.
► Application Areas
Tirzepatide: Primarily used to treat type 2 diabetes and obesity, reducing cardiovascular disease risk by improving glycaemic control and weight loss outcomes.
Retatrutide: Also indicated for type 2 diabetes and obesity, with greater potential in obesity treatment due to its more pronounced weight reduction effects.
Lemon bottle peptide (if its core component is a lipolytic peptide): Primarily employed for localised fat reduction and body contouring, such as diminishing double chins, defining jawlines, and addressing abdominal and thigh fat deposits.
Common Ground: All three agents address metabolic health and body composition improvement. While their specific applications differ, they collectively aim to enhance overall health and quality of life.